Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis
- Submitting institution
-
University of Sussex
- Unit of assessment
- 5 - Biological Sciences
- Output identifier
- 427961_73250
- Type
- D - Journal article
- DOI
-
10.15252/emmm.201505986
- Title of journal
- EMBO Molecular Medicine
- Article number
- -
- First page
- 407
- Volume
- 8
- Issue
- 4
- ISSN
- 1757-4676
- Open access status
- Out of scope for open access requirements
- Month of publication
- March
- Year of publication
- 2016
- URL
-
https://doi.org/10.15252/emmm.201505986
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
19
- Research group(s)
-
-
- Citation count
- 33
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Edward Wright's laboratory collaborated with a Swiss biotech company (Humabs Biotech, now Vir Biotechnology) to develop new treatments for people exposed to rabies and other lyssavirus species. Using the viral pseudotyping assays established in the laboratory, they identified monoclonal antibodies that could neutralise a broad range of lyssavirus species, not possible using other assays. Furthermore, Edward Wright's laboratory made epitope mutants of the viruses that helped map the binding sites for the most promising antibodies, enabling the most promising cocktail to be selected for further development.
Edward Wright critically analyzed the data and contributed in the writing of the manuscript.
- Non-English
- No
- English abstract
- -